Login
Companies $AYTU
$2.61 +$0.79 (43.43%) After hours
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC

aytubio.com

What Do They Do?

Sells extended-release ADHD medicines, along with a depression medicine and an allergy treatment, to wholesalers and pharmacies.

Who Are Their Customers?

The company sells prescription medicines through wholesalers and distributors and also directly to pharmacy customers.

Do Revenues Turn Into Profits?

Not on paper. It lost $14.3M in FY2026, but brought in more cash than it spent: $3.3M of free cash flow.

Operating income, FY2026
−14% of revenue
▼ −6% (Loss) vs FY2025 (−$7.8M, −12%)
Net income, FY2026
−25% of revenue
▼ −5% (Loss) vs FY2025 (−$13.6M, −20%)
Free cash flow, FY2026
6% of revenue
▲ Turned profitable vs FY2025 (−$2.2M, −3%)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Revenue
▲ +7%
vs $13.9M in Q1 FY2026
Net income
▼ Turned to a loss
vs $2M in Q1 FY2026

Consumer Health exit The older report described prescription drugs and consumer health products sold directly to consumers. The latest report describes a prescription-focused business after the Consumer Health wind-down and divestiture.

Added depression treatment The latest report adds EXXUA, a depression medicine, to the commercial portfolio and makes it the centerpiece of sales efforts; the older report described ADHD and pediatric prescription portfolios.

Who Do They Compete With?

Competes with Granules

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support